Tempus AI Shows Short-Term Momentum Amid Profitability Concerns and Technical Support Test

Technical Analysis

Tempus AI (NASDAQ: TEM) closed at $52.90 on April 25, 2025, down 1.12%, after reaching an intraday high of $54.55 and a low of $52.22. The stock remains above its 50-day moving average of $52.59 and its 200-day moving average of $49.96, signaling a short to mid-term bullish trend. The relative strength index (RSI) at 65 is approaching overbought territory but has not yet exceeded it, suggesting moderate upward momentum. The MACD remains negative at -3.60, indicating some underlying bearish momentum over the past three months. Average true range (ATR) of 9.08 points points to significant price volatility. Key technical support is near $52.73, just below the current price, with resistance identified at $57.39. Given the moderate trading volume at 8.94 million, below the 13.5 million average, volatility may ease in the short term.

For the next trading day (April 28), the stock could test support around $52.73 with potential for a bounce, barring negative market catalysts. Over the upcoming week, momentum from recent news-driven rallies may sustain buying interest, targeting the resistance zone near $57. However, the stock may face consolidation around $53–$55 due to profit-taking after the 21% surge earlier in the week.

Fundamental Analysis

Tempus AI currently operates with a market capitalization of approximately $8.89 billion. Earnings per share remain negative at -$6.23 over the trailing twelve months, and the price-to-earnings (PE) ratio is negative at -8.49, reflecting ongoing losses inherent in this high-growth AI and precision medicine sector company. The discounted cash flow (DCF) model also yields a negative intrinsic value estimate (-31.53), indicating that discounted expected cash flows do not cover the current valuation, driven largely by persistent unprofitability and significant R&D investments.

Recent positive developments include an $200 million strategic partnership with AstraZeneca and Pathos AI focused on multimodal AI oncology foundation models, and successful acceptance of 18 abstracts for presentation at a major oncology conference (AACR 2025). These underscore Tempus AI’s leadership in AI-driven precision medicine and enhance its long-term growth prospects. The company’s upcoming Q1 2025 earnings on May 6 will be a critical event for validating progress and future guidance.

Analyst consensus leans toward a Hold rating, with price targets ranging from $55 to $65 and a median of $58. The stock has shown strong short-term momentum but remains speculative given the lack of positive earnings and reliance on future breakthroughs and partnerships for value creation.

Intrinsic Value and Long-Term Investment Potential

Despite current losses and a negative DCF, Tempus AI’s intrinsic value should be considered in the context of its disruptive potential in oncology AI and precision medicine. The company’s partnerships and scientific advancements position it well to capitalize on a growing market. However, significant execution risk remains. Investors with a long-term horizon may find value in the stock if Tempus can achieve profitable scalability and broaden commercial adoption, but at present, the stock reflects a premium on future growth rather than current fundamentals.

The path to intrinsic value realization depends on successful monetization of AI-driven healthcare solutions, margin improvement, and sustainable revenue streams. Market conditions, emerging competition, and regulatory developments could impact this trajectory materially.

Overall Evaluation

Tempus AI presents a technically supported growth story with solid momentum but fundamental challenges in profitability and valuation. The stock’s recent price surge fueled by strategic partnerships and scientific validations has met some resistance near $55–$57. The consensus analyst sentiment and technical indicators suggest a cautious stance, acknowledging upside potential balanced by near-term volatility and financial risks.

Classifying the stock as a Hold candidate is consistent with the prevailing analyst consensus. The rationale includes the current overbought signals, ongoing negative earnings, and the stock’s dependence on forthcoming earnings results and partnership execution to sustain gains. Investors monitoring the May 6 earnings for clearer signals on financial progression may consider maintaining positions but should be vigilant to price action around support levels near $52.73.

In summary, Tempus AI exhibits promising innovation and market positioning but remains in a formative stage regarding financial returns and intrinsic value capture. The Hold categorization reflects balanced risks and rewards for both short-term trading and long-term investment perspectives.